Supplementary Tables and Figures from Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression

1.Supplementary Table S1. Master Regulators of FL transformation to DLBCL. 2.Supplementary Table S2. qRT-PCR analysis of MR mRNA expression after silencing of in SUDHL6. 3.Supplementary Table S3. Selected drugs based on the similarity of drug treatment signatures vs siRNA knockdown. 4.Supplementary Table S4. Primers used for qRT-PCR. 5.Supplementary Figure S1. Unsupervised hierarchal clustering using gene expression data for FL, t-DLBCL samples (based on BCL2 translocation information), and cell lines SUDHL4, SUDHL6, VAL and CB33 obtained from (28). 6.Supplementary Figure S2. Expression and silencing of MRs in B-lymphoma cell lines 7.Supplementary Figure S3. Expression of activated MRs at the protein level in DLBCL patients and B-lymphoma cell lines 8.Supplementary Figure S4. Drug dose dependent cell viability in B-lymphoma cell lines.